A new synthetic inhibitor of heat shock protein 90 (Hsp90), SNX-5422 is under development by Serenex. It is orally administered (pill form). Once in the body, SNX-5422 is converted to SNX-2122; that is, SNX-5422 is a prodrug of SNX-2112, which is the active form.
To download a fall 2006 poster presented by Serenex at the EORTC meeting, click here. Once you open the pdf, use the magnification control to enlarge the fonts for easier reading.
For information at the site of the manufacturer, click here.
A phase I trial of SNX-5422 opened in late May, 2007. According to Serenex, this first phase 1 study will be a dose escalating trial involving up to 50 patients. The trial will evaluate safety, pharmacokinetic and pharmacodynamic properties of SNX-5422. This clinical trial will be conducted at the TGen Clinical Research Services at Scottsdale Healthcare in Scottsdale, AZ and at the Sarah Cannon Research Institute in Nashville, TN.
See more details about the trial at this link: clinicaltrials.gov